Market Cap (In USD)
2.68 Million
Revenue (In USD)
-
Net Income (In USD)
-3.3 Million
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.6404-6.404
- PE
- -0.8654
- EPS
- -0.74
- Beta Value
- 0.469
- ISIN
- IL0011284614
- CUSIP
- -
- CIK
- -
- Shares
- 4193690.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Asaf Shiloni
- Employee Count
- -
- Website
- https://www.kadimastem.com
- Ipo Date
- 2021-02-01
- Details
- Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.
More Stocks
-
HXBMHelix BioMedix, Inc.
HXBM
-
YAARI
-
688356Jenkem Technology Co., Ltd.
688356
-
ESTAR
-
KANSAINERKansai Nerolac Paints Limited
KANSAINER
-
FRONTSPFrontier Springs Limited
FRONTSP
-
WRKSTheWorks.co.uk plc
WRKS
-
JOMA